Reply to: "Biejia-Ruangan compound and incidence of hepatocellular carcinoma"

Affiliations

¹ Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
² Liver Disease Department, The Second People's Hospital of Fuyang City, Fuyang, Anhui, China.
³ Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. Electronic address: yongpingyang@hotmail.com.

Comment

Dong Ji et al. J Hepatol. 2023 Apr.

. 2023 Apr;78(4):e142-e144.

doi: 10.1016/j.jhep.2023.01.003. Epub 2023 Jan 13.

¹ Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
² Liver Disease Department, The Second People's Hospital of Fuyang City, Fuyang, Anhui, China.
³ Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. Electronic address: yongpingyang@hotmail.com.

No abstract available

Comment on

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y. Ji D, et al. J Hepatol. 2022 Dec;77(6):1515-1524. doi: 10.1016/j.jhep.2022.07.018. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35985545 Clinical Trial.
Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
Luo L, Yao X, Yang W. Luo L, et al. J Hepatol. 2023 Apr;78(4):e141-e142. doi: 10.1016/j.jhep.2022.11.012. Epub 2022 Nov 17. J Hepatol. 2023. PMID: 36402448 No abstract available.